Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lifecare AS ( (DE:LFC0) ) just unveiled an announcement.
Lifecare ASA has received approval from the Financial Supervisory Authority of Norway for its EEA prospectus related to a previously announced, partially underwritten rights issue of new shares. The prospectus will be made available to eligible investors ahead of the subscription period, which runs from 7 to 21 January 2026, with DNB and SB1 Markets acting as managers. The transaction, approved by an extraordinary general meeting, is a key step in securing new equity for the company, potentially strengthening its balance sheet and supporting further development and commercialization of its medical sensor and continuous glucose monitoring technologies, although the offering is subject to standard jurisdictional restrictions and is not being made in markets such as the United States, Canada, Japan and Australia.
More about Lifecare AS
Lifecare ASA is a Norwegian medical sensor company developing technology for sensing and monitoring various body analytes, with a primary focus on bringing next-generation continuous glucose monitoring (CGM) systems to market. Its sensor platform, based on osmotic pressure as the sensing principle, is designed to detect and track a broad range of analytes and molecules in humans and pets, positioning the company within the high-growth digital health and glucose monitoring segments.
Average Trading Volume: 406,510
Current Market Cap: NOK219M
Learn more about LFC0 stock on TipRanks’ Stock Analysis page.